In this article:

Roivant Sciences (ROIV) Receives a Buy from H.C. Wainwright

In this article:
In this article:

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Roivant Sciences (ROIVResearch Report), with a price target of $14.00. The company’s shares closed last Monday at $7.20, close to its 52-week low of $5.80.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 3.0% and a 39.0% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roivant Sciences with a $14.50 average price target.

See today’s best-performing stocks on TipRanks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Montes Archimedes Acquisition Corp is a blank check company.

Read More on ROIV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed